Singapore, May 20 -- TheBioMedX Institutehas announced the launch of a new global call for research proposals in collaboration withBoehringer Ingelheimto establish an independent research group focused on the development of aNew Platform for Next-Generation Intraocular Biologics.

This new initiative marks the second research initiative at the XSeed Labs incubator, located atBoehringer Ingelheim's research and development site in Ridgefield, Conn.

While current biologic therapies have significantly improved the treatment of retinal diseases, the burden of frequent intraocular injections remains a substantial barrier to patient adherence. This joint effort will address critical unmet needs in ophthalmic drug development: the challenge of ...